Лучшие больницы для «Brain Cancer Treatment» в Ченнаи, Индия

Brain cancer refers to malignant neoplasms originating within the central nervous system (primary brain tumors) or metastasizing to the brain from systemic cancers such as lung, breast, or melanoma (secondary/metastatic brain tumors). Primary brain tumors are classified by the WHO 2021 CNS tumor classification, which integrates histological morphology with molecular markers — including IDH1/IDH2 mutation status, MGMT promoter methylation, 1p/19q codeletion, TERT promoter mutations, and EGFR amplification — to define tumor grade and predict treatment response. Glioblastoma multiforme (GBM, WHO Grade IV) is the most aggressive primary brain tumor, with a median survival of 14–16 months under standard Stupp protocol (concurrent temozolomide chemotherapy with radiotherapy followed by adjuvant temozolomide cycles). Lower-grade gliomas (WHO Grade II–III), meningiomas, pituitary adenomas, and medulloblastomas carry substantially better prognoses and often respond well to surgical resection alone or combined modality therapy.

• **Confirmed or suspected brain tumor on neuroimaging**: Patients with MRI brain with gadolinium contrast demonstrating a space-occupying lesion requiring histopathological diagnosis or definitive treatment.
• **Newly diagnosed or recurrent primary brain tumors**: Including glioblastoma (GBM), anaplastic astrocytoma, oligodendroglioma, meningioma (Grade I–III), medulloblastoma, ependymoma, or PCNSL (primary CNS lymphoma).
• **Resectable tumors in non-eloquent cortex**: Candidates for craniotomy with awake brain surgery when lesions are near speech or motor cortex.
• **Unresectable or deep-seated tumors**: Suitable for stereotactic biopsy, Gamma Knife radiosurgery, or CyberKnife SBRT (e.g., thalamic, brainstem, or basal ganglia tumors).
• **Brain metastases (1–4 lesions)**: Candidates for stereotactic radiosurgery (SRS) ± whole-brain radiotherapy (WBRT) or surgical resection if single large symptomatic metastasis.
• +2 more

- MRI brain with and without gadolinium contrast (standard 3T; preferably 7T if available)

- MR spectroscopy, MR perfusion, and functional MRI (fMRI) for eloquent cortex mapping

**1. Craniotomy with Maximal Safe Resection (Open Surgery)**

The gold standard for most resectable supratentorial and posterior fossa tumors. Performed under general anesthesia with neuronavigation (Brainlab or Medtronic StealthStation) for real-time 3D intraoperative guidance. Key adjuncts include:

• **5-ALA (5-aminolevulinic acid) fluorescence-guided surgery**: Oral 5-ALA administered 3–4 hours pre-op causes selective accumulation of protoporphyrin IX in malignant glioma cells, which fluoresce pink under blue-violet light, enabling the surgeon to distinguish tumor from normal brain and achieve higher rates of gross total resection (GTR).
• **Intraoperative MRI (iMRI)**: Real-time 1.5T or 3T MRI suite integrated into the operating room allows the surgeon to identify residual enhancing tumor during the same operative session, improving GTR rates from ~60% to >80%.
• **Intraoperative Neurophysiological Monitoring (IONM)**: Continuous motor evoked potentials (MEPs), somatosensory evoked potentials (SSEPs), and direct cortical stimulation mapping protect eloquent cortex and corticospinal tracts during resection.
• **Awake Craniotomy with Cortical Mapping**: For tumors within or adjacent to speech (Broca's/Wernicke's), motor, or sensory cortex. The patient is kept awake during a critical phase for real-time language and motor testing, allowing aggressive resection while preserving neurological function.
• **Carmustine (BCNU) Wafers (Gliadel)**: Biodegradable polymer wafers impregnated with carmustine chemotherapy placed directly into the tumor resection cavity at the time of surgery, providing sustained local chemotherapy delivery for GBM.

**2. Stereotactic Radiosurgery (SRS) — Gamma Knife, CyberKnife, Novalis TX**

**Phase 1 — Pre-Arrival & Remote Evaluation (2–4 weeks before travel)**

• GAF Healthcare coordinates submission of all existing imaging (MRI DICOM files, PET-CT), histopathology reports, molecular panel results, and clinical records to the designated neuro-oncology MDT at the chosen hospital.
• Neuro-oncologist and neurosurgeon conduct a remote teleconsultation (video call) to review the case, determine operability, define the proposed treatment strategy, and issue a formal Treatment Plan & Cost Estimate.
• Pre-surgical anaesthesia risk assessment form completed; additional investigations (cardiac ECHO, pulmonary function tests) requested if indicated by comorbidities.
• GAF Healthcare initiates e-Medical Visa application (India) or entry visa facilitation (UAE) — see Logistics section.

**Phase 2 — Arrival & Pre-Operative Work-Up (Days 1–3 in country)**